1,25(OH)2D3对宫颈癌作用的研究进展
The Research Progress of 1,25(OH)2D3 Effects on Cervical Cancer
DOI: 10.12677/ACRPO.2016.54006, PDF, HTML, XML, 下载: 2,018  浏览: 4,582 
作者: 周文文, 杨雁鸿*：秦皇岛市第一医院，河北 秦皇岛；王真真, 冯 博, 冯 悦, 李倩影, 王小玉：承德医学院研究生院，河北 承德
关键词: 1；25(OH)2D3；宫颈癌；维生素D；1；25(OH) 2D3； Cervical Cancer； Vitamin D
摘要: 宫颈癌是目前常见的妇科恶性肿瘤之一，近年来由于人乳头瘤病毒(HPV)感染率的上升、人类生存环境的不断恶化等原因，宫颈癌的发病率呈现快速增高趋势，早期宫颈癌多采用手术治疗，晚期患者多采用手术联合放化疗等治疗方案。但是目前临床上用的化疗药物多具有较严重的毒性，限制了其临床应用。因此寻找新的、副作用小的药物是肿瘤研究的方向之一。近年来研究发现1,25(OH)2D3具有明显的抗肿瘤作用，现将其抗肿瘤效应及在宫颈癌方面的应用作一综述，为宫颈恶性肿瘤的临床治疗提供新的思路和理论依据。
Abstract: Cervical cancer is one of common gynecological malignancies. In recent years, due to the rise of human papillomavirus (HPV) infection rates, the worsening of the human environment and other reasons, the incidence of cervical cancer showed a rapid increasing trend. Early cervical cancer is usually treated by surgery, while patients of advanced disease use surgery combining with radiotherapy and chemotherapy and other treatment options. But the chemotherapy drugs currently used in clinical practice have more serious toxicity, limiting its clinical application. Therefore, the search for drugs of new and few side effects is one of the directions of cancer research. Recent studies have found that 1,25(OH)2D3 has significant anti-tumor effect, and now its anti-tumor effects in cervical cancer and its application are reviewed, to provide new ideas and theoretical basis for the clinical treatment of cervical cancer.
文章引用：周文文, 王真真, 杨雁鸿, 冯博, 冯悦, 李倩影, 王小玉. 1,25(OH)2D3对宫颈癌作用的研究进展[J]. 亚洲肿瘤科病例研究, 2016, 5(4): 55-60. http://dx.doi.org/10.12677/ACRPO.2016.54006

参考文献

[1] 王丽萍, 黄金. 维生素D与肥胖关系的研究进展[J]. 中国全科医学, 2014, 17(14): 1581-1583.
[2] 蒋普, 蒋迎九. 1,25二羟基维生素D3对肺癌的抑制作用[J]. 检验医学与临床, 2013, 10(8): 998-1000.
[3] Ray, R. and Lambert, J.R. (2011) 1α,25-Dihydroxyvitamin D3-3β-Bromoacetate, a Potential Cancer Therapeutic Agent: Synthesis and Molecular Mechanism of Action. Bioorganic & Medicinal Chemistry Letters, 21, 2537-2540.
http://dx.doi.org/10.1016/j.bmcl.2011.02.025
[4] 崔健, 陈虹, 黄秉仁. 维生素D受体最新研究进展[J]. 生理科学进展, 2011, 42(2): 95-99.
[5] Holick, M.F. (2004) Vitamin D: Importance in the Prevention of Cancers, Type 1 Diabetes, Heart Disease, and Osteoporosis. American Journal of Clinical Nutrition, 79, 362-371.
http://dx.doi.org/10.1016/j.bmcl.2011.02.025
[6] Demay, M.B. (2006) Mechanism of Vitamin D Receptor Action. Annals of the New York Academy of Sciences, 1068, 204-213.
http://dx.doi.org/10.1196/annals.1346.026
[7] 马淑状. PTEN Ki-67 Bax蛋白与卵巢肿瘤关系的研究[D]: [硕士学位论文]. 太原: 山西医科大学, 2009.
[8] Prudencio, J., Akutsu, N., et al. (2001) Action of Low Calcemic 1,25-Dihydroxyvitamin D3 Analogue EBl089 in Head and Neck Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute, 93, 745-753.
http://dx.doi.org/10.1093/jnci/93.10.745
[9] Beer, T.M. and Myrthue, A. (2004) Calcitriol in Cancer Treatment: From the Lab to the Clinic. Molecular Cancer Therapeutics, 3, 373-381.
[10] Eelen, G. (2007) Mechanism and Potential of the Growth-Inhibitory Actions of Vitamin D and Analogs. Current Medicinal Chemistry, 14, 1893-1910.
http://dx.doi.org/10.2174/092986707781058823
[11] Lu, H.Q. and Zheng, J. (2006) Synergistic Inhibitory Effect of All-Trans Retinoic Acid and l,25-Dihydroxy Vitamin D3 on Growth of Human Hepatoma Cell Line HepG2. Ai Zheng, 25, 1470-1476.
[12] Li, P., Li, C., Zhao, X., et al. (2004) p27(Kip1) Stabilization and G(1) Arrest by 1,25-Dihydroxyvitamin D(3) in Ovarian Cancer Cells Mediated through Down-Regulation of Cyclin E/Cyclin-Dependent Kinase 2 and Skp1-Cullin-F-Box Pro-tein/Skp2 Ubiquitin Ligase. Journal of Biological Chemistry, 279, 25260-25267.
http://dx.doi.org/10.1074/jbc.M311052200
[13] Hughes, P.J., Lee, J.S., Reiner, N.E., et al. (2008) The Vitamin D Recep-tor-Mediated Activation of Phosphatidylinositol 3-Kinase (PI3Kalpha) Plays a Role in the 1alpha,25-Dihydroxyvitamin D3-Stimulated Increase in Steroid Sulphatase Activity in Myeloid Leukaemic Cell Lines. Journal of Cellular Biochemistry, 103, 1551-1572.
http://dx.doi.org/10.1002/jcb.21545
[14] 胡志勇, 周逸鹏, 黎书炜, 等. 1,25-二羟基维生素D3增强卡铂对人肺癌A549细胞的杀伤效果[J]. 肿瘤防治研究, 2013, 40(2): 125-130.
[15] Pacher, P. and Hajnóczky, G. (2001) Propagation of the Apoptotic Signal by Mitochondrial Waves. EMBO Journal, 20, 4107-4121.
http://dx.doi.org/10.1093/emboj/20.15.4107
[16] Blutt, S.E., McDonnell, T.J., Polek, T.C. and Weigel, N.L. (2000) Calcitriol Induced Apoptosis in LNCaP Cells Is Blocked by Overexpression of Bcl-2. Endocrinology, 141, 10-17.
[17] Verlinden, L., Verstuyf, A., VanCamp, M., et al. (2000) Two Novel 14-Epianalogues of 1,25-Dihydroxyvitamin D3 Inhibit the Growth of Human Breast Cancer Cells in Vitro and in Vivo. Cancer Research, 60, 2673-2679.
[18] Pirianov, G. and Cilston, K.W. (2001) Interaction of Vitamin D Analogs with Signing Path Way Leading to Active Cell Death in Breast Cancer Cell. Steroids, 66, 309-318.
http://dx.doi.org/10.1016/S0039-128X(00)00201-4
[19] 段娥. 维生素D及其受体与妇科肿瘤[J]. 国外医学妇产科学杂志, 2005, 32(4): 213-216.
[20] Koli, K. and Keski, O.J. (2000) 1 Alpha,25-Dihydroxy Vitamin D3 and Its Analogues down Regulate Cell Invasion-Associated Protease in Cult Ured Malignant Cells. Cell Growth & Differentiation, 11, 221-229.
[21] Ben-Shoshan, M., Amir, S., Dang, D.T., et al. (2007) 1 Alpha,25-Dihydroxyvitamin D3(Calcitriol)Inhibits Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway in Human Cancer Cells. Molecular Cancer Therapeutics, 6, 1433-1439.
http://dx.doi.org/10.1158/1535-7163.MCT-06-0677
[22] Bemd, G.J. and Chang, G.T. (2002) Vitamin D and Vitamin D Analogs Cancer Treatment. Curt Drug Targets, 3, 85- 94.
http://dx.doi.org/10.2174/1389450023348064
[23] Kumagai, T., O’Kelly, J., Said, J.W., et al. (2003) Vitamin D3 Analog 19-Nor-1,25-Dihydroxyvitamin D2: Antitumor Activity against Leukemia, Myeloma, Andcolon Cancer Cells. National Cancer Institute, 95, 896-905.
http://dx.doi.org/10.1093/jnci/95.12.896
[24] Molnar, I., Kute, T., Willingham, M.C., et al. (2003) 19-Nor-1 Alpha,25 Dihydroxyvitamin D2(Paricalcitol): Effects on Clonal Proliferation, Differentiation, and Apoptosis in Human Leukemic Cells. Cancer Research and Clinical Oncology, 129, 35-42.
[25] Light, B.W., Yu, W.D. and Mariann, C. (1997) Potentiation of Cisplatin Antitumor Activity Using a Vitamin D Analogue in a Murine Squamous Cell Carcinoma Model System. Cancer Research, 57, 3759-3764.
[26] Reichrath, J., Rafi, L., Muller, S.M., et al. (1998) Immunohistochernical Analysis of 1,25-Dihydroxyvitamin D3 Receptorin Cervical Carcinoma. Histochern, 30, 561-567.
http://dx.doi.org/10.1023/A:1003283117492
[27] 侯萍, 张燕, 高伟, 姜常青. 维生素D受体在宫颈癌中的表达及临床意义[J]. 中国煤炭工业医学杂志, 2009, 12(5): 694-696.
[28] 张凤, 邢丽娜, 马艳伟, 等. 1,25-二羟基维生素D3对鼠宫颈癌免疫作用的研究[J]. 哈尔滨医科大学学报, 2015, 49(1): 30-33.
[29] 于君丽, 刁尧, 郭科军, 等. 钙与维生素D3抑制人宫颈癌细胞和组织增殖作用的相关性研究[J]. 中国医科大学学报, 2005, 34(5): 403-405.
[30] 林兰, 林锦贤, 余江, 林善英. 人宫颈癌SiHa细胞核维生素D受体的检测[J]. 福建医药杂志, 2012, 34(4): 73-75.
[31] 蔡叶樨, 张红河, 倪慧群, 徐庆嵩. 血浆Th17细胞相关因子与25-羟基维生素D检测对宫颈癌的临床价值[J]. 全科医学临床与教育, 2014, 12(3): 263-265.
[32] 应倩, 夏庆民, 郑荣寿, 张思维, 陈万青. 中国2009年宫颈癌发病与死亡分析[J]. 中国肿瘤, 2013, 22(8): 612- 616.
[33] 石远凯, 孙燕. 临床肿瘤内科手册[M]. 第6版. 北京: 人民卫生出版社, 2015.
[34] 陈秀慧, 曲军英. 不同质量浓度顺铂对宫颈癌Hela细胞增殖能力的影响[J]. 中国临床药理学杂志, 2014, 30(7): 601-602.
[35] Wang, T.H., Wang, J.Y., Gong, X., Li, H.Z. and Cheng, Y. (2012) Tetrandrine Enhances Cytotoxicity of Cisplatin in Human Drug-Resistant Esophageal Squamous Carcinoma Cells by Inhibition of Multidrug Resistance-Associated Protein l. Oncology Reports, 5, 1681-1686.